(Q54672869)

English

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers.

scientific article published on 20 May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

5

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

kConFab Investigators

4

object named as

kConFab Investigators

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

author name string

Max Yan

1

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

Mukta Rayoo

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

Elena A Takano

3

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

language of work or name

0 references

publication date

20 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

126

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

2

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

395-405

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

https://scigraph.springernature.com/pub.10.1007/s10549-010-0941-9

0 references

p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Triple-negative breast cancer: risk factors to potential targets

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

The evolving role of oestrogen receptor beta in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Distinct expression patterns of ER alpha and ER beta in normal human mammary gland

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen Receptor-Beta Expression in Hereditary Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

ERbeta in breast cancer--onlooker, passive player, or active protector?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

ERbeta has nongenomic action in caveolae

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

ERbeta exerts multiple stimulative effects on human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Plasma membrane estrogen receptors exist and functions as dimers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Adaptation of energy metabolism in breast cancer brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Functional estrogen receptors in the mitochondria of breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen actions on mitochondria--physiological and pathological implications

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Transcription-independent pro-apoptotic functions of p53.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Modulation of mitochondrial Ca(2+) uptake by estrogen receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen receptor beta as a mitochondrial vulnerability factor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0941-9

21 January 2018

Identifiers

10.1007/S10549-010-0941-9

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

release_vkvlmpl6ungmrhnf2wrknuuyqu

1 reference

https://api.fatcat.wiki/v0/release/vkvlmpl6ungmrhnf2wrknuuyqu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 June 2018

http://europepmc.org/abstract/MED/20490651

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54672869&oldid=1844443127"